Star Scientific, Inc. (Nasdaq:CIGX) reports the publication of the first peer-reviewed article on the in-vitro and in-vivo activity of anatabine in Alzheimer's Disease. The article is authored by scientists at the Roskamp Institute and is electronically published in the European Journal of Pharmacology (2011 Sept 19). It states that anatabine lowers Alzheimer's A-beta production in-vitro and in-vivo.

Star Scientific, Inc., together with its subsidiaries, engages in the development, implementation, and licensing of tobacco curing technology that prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines (TSNA).

Read the full article and the disclaimer at: http://drstockpick.com/?p=22400